- Home
- PMN vs SRG Comparison
PMN vs SRG Comparison
Compare PMN & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMN | SRG |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.5M | 146.4M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PMN | SRG |
|---|---|---|
| Price | $13.79 | $2.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | 22.9K | ★ 120.5K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,204,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.30 |
| 52 Week Low | $0.29 | $2.05 |
| 52 Week High | $27.40 | $4.56 |
Technical Indicators
Market Signals| Indicator | PMN | SRG |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 28.72 |
| Support Level | $12.89 | $2.05 |
| Resistance Level | $15.50 | $2.74 |
| Average True Range (ATR) | 0.87 | 0.07 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 6.33 | 7.89 |
Price Performance
Historical ComparisonAbout PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.